ReviewImmunotherapy2010
Immunotherapy of systemic sclerosis.
Review in Immunotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Current opinion in rheumatology · 2015Pooled it
- Evaluating the role of active TGF-β1 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study.Advances in rheumatology (London, England) · 2024Article
- Serum lysyl oxidase concentration increases in long-standing systemic sclerosis: Can lysyl oxidase change over time?Archives of rheumatology · 2022Article
- Upcoming treatments for morphea.Immunity, inflammation and disease · 2021Review
- Dysphagia, reflux and related sequelae due to altered physiology in scleroderma.World journal of gastroenterology · 2021Review
- Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.Scientific reports · 2021Article
- Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.Nature reviews. Rheumatology · 2019Review
- Positive effect of ozonotherapy on serum concentration of soluble interleukin-2 receptor and neopterin in patients with systemic sclerosis.Postepy dermatologii i alergologii · 2019Article
- Role of the mTOR pathway in minor salivary gland changes in Sjogren's syndrome and systemic sclerosis.Arthritis research & therapy · 2018Article
- Protein Tyrosine Phosphatases in Systemic Sclerosis: Potential Pathogenic Players and Therapeutic Targets.Current rheumatology reports · 2017Review
- Early Endothelial Progenitor Cells (eEPCs) in systemic sclerosis (SSc) - dynamics of cellular regeneration and mesenchymal transdifferentiation.BMC musculoskeletal disorders · 2016Article
- Scleroderma renal crisis during intravenous cyclophosphamide pulse therapy for complicated interstitial lung disease was successfully treated with angiotensin converting enzyme inhibitor and plasma exchange.Nagoya journal of medical science · 2016Article
- Current perspectives on the immunopathogenesis of systemic sclerosis.ImmunoTargets and therapy · 2016Review
- Article
- Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.Arthritis research & therapy · 2014Article
- Animal models of systemic sclerosis: their utility and limitations.Open access rheumatology : research and reviews · 2014Review
- Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease.BioMed research international · 2014Article
- Immunosuppression for interstitial lung disease in systemic sclerosis.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease.Antioxidants & redox signaling · 2013Review
- The immune pathogenesis of scleroderma: context is everything.Current rheumatology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Scleroderma is a multisystem autoimmune disease characterized by an abnormal immune activation associated with the development of underlying vascular and fibrotic disease manifestations. This article highlights the current use of drugs targeting the immune system in scleroderma. Nonselective immunosuppression, and in particular cyclophosphamide, remains the main treatment for progressing skin involvement and active interstitial lung disease. Mycophenolate mofetil is a promising alternative to cyclophosphamide. The use of cyclosporine has been limited by modest efficacy and serious renal toxicity. Newer T-cell (sirolimus and alefacept) and B-cell (rituximab)-targeted therapies have provided some encouraging results in small pilot studies. Hematopoietic stem cell transplantation can be effective for severe fibrotic skin disease, but toxicity remains a concern. Clinical efficacy and safety of antifibrotic treatments (e.g., imatinib) await confirmation. Newer biological agents targeting key molecular or cellular effectors in scleroderma pathogenesis are now available for clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.